Why the study?
The prognostic value of pancreatic T2* MRI for predicting cardiac events in patients with transfusion-dependent thalassemia was evaluated.
Does pancreatic T2* MRI predict cardiac arrhythmias in patients with transfusion-dependent thalassemia?
Does pancreatic T2* MRI predict cardiac arrhythmias in patients with transfusion-dependent thalassemia?
Pancreatic T2* MRI is a significant independent predictor of future cardiac arrhythmias in patients with transfusion-dependent thalassemia, with an optimal cut-off of < 6.73 ms.
Pancreatic T2* MRI may refine cardiac event prediction in TDT; leaves open incremental value over standard iron monitoring.
We assessed the value of pancreatic T2* magnetic resonance imaging (MRI) for predicting cardiac events from a large prospective database of transfusion-dependent thalassemia (TDT) patients. We considered 813 TDT patients (36.47 ± 10.71 years, 54.6% females) enrolled in the Extension-Myocardial Iron Overload in Thalassemia Network. MRI was used to measure hepatic, pancreatic, and cardiac iron overload (IO), to assess biventricular function and atrial dimensions, and to detect replacement myocardial fibrosis. The mean follow-up was 50.51 ± 19.75 months. Cardiac complications were recorded in 21 (2.6%) patients: one with heart failure (HF) and 20 with arrhythmias. The single patient who developed HF had, at the baseline MRI, a reduced pancreas T2*. Out of the 20 recorded arrhythmias, 17 were supraventricular. Pancreatic T2* values were a significant predictor of future arrhythmia-related events (hazard ratio = 0.89; p = 0.015). Pancreas T2* remained significantly associated with future arrhythmias after adjusting for any other univariate predictor (age and male sex, diabetes, history of previous arrhythmias, or left atrial area index). According to the receiver-operating characteristic curve analysis for arrhythmias, a pancreas T2* < 6.73 ms was the optimal cut-off value. In TDT, pancreatic iron levels had significant prognostic power for arrhythmias. Regular monitoring and the development of targeted interventions to manage pancreatic IO may help improve patient outcomes.
No takes yet. Share an insight, caveat, or question.
Meloni et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: